---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010321"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:19:41.578559+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroBo licenses NB-01 to MThera Pharma for diabetic neuropathy; terms undisclosed

## Summary
- Exclusive license grants MThera rights to develop and commercialize NB-01 for painful diabetic neuropathy.
- MThera may conduct a Phase 3 trial in the U.S. and South Korea; NeuroBo to focus on DA-1726 and DA-1241.
- Phase 2 efficacy data cited by MThera; financial terms not disclosed.
- NeuroBo CEO says deal reflects commitment to out-license legacy assets.

## SEC filing metadata
- accession: 0001558370-24-010321
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024010321/0001558370-24-010321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024010321/nrbo-20240730x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010321
- JSON: https://secwatch.observer/filing/0001558370-24-010321.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.